Laurence J. Downey, MD Joins Arbor Pharmaceuticals as Vice President of Medical Affairs

ATLANTA, Oct. 27 /PRNewswire/ -- Arbor Pharmaceuticals, a specialty pharmaceutical company based in Atlanta, GA, announced today that Laurence J. Downey, MD has joined the company as Vice President of Medical Affairs. Dr. Downey is a thirty year veteran of the industry and previously had a long and successful career at Solvay Pharmaceuticals (now part of Abbott Laboratories) including the leadership positions of President and CEO of the U.S. and Canadian operations. Prior to that, Dr. Downey held positions in Medical Affairs, Commercial Operations and Research and Development at Solvay. Most recently, he was CEO of Ketal Biomedical, Inc.

Dr. Downey is a native of the UK and obtained his medical degree from the University of Manchester. He worked as a family practitioner before joining the pharmaceutical industry and moving to the United States in 1986. He is a Fellow of the Faculty of Pharmaceutical Physicians of the UK and a graduate of the Advanced Management Program at Harvard Business School. He was recently chair of the Georgia Bioscience Commercialization Center and also co-chairs the Metro Atlanta Chamber's vaccine sub-committee.

Ed Schutter, President and CEO of Arbor commented, "We are thrilled that Dr. Downey has accepted the opportunity to join Arbor and to lead all medical related aspects of our company. Dr. Downey has a wealth of industry experience and will be a valuable member of our leadership team in many ways."

Dr. Downey, added, "I'm very pleased to be joining Arbor and am personally excited about the opportunity for this young company. In addition to an experienced and successful management team, Arbor has an impressive board of industry veterans which together are unsurpassed for a specialty pharmaceutical company. I look forward to making an impact and helping Arbor achieve its ambitious goals."

About Arbor Pharmaceuticals, Inc.

Arbor Pharmaceuticals, headquartered in Atlanta, Georgia, is a specialty pharmaceutical company currently focused primarily on the growing pediatric market. The company intends to become a leading specialty pharmaceutical company by actively licensing, developing and commercializing late-stage products for specialty focused conditions. Arbor currently markets three nonantibiotic products for varying otic conditions including XYLAREX®, ZINOTIC® and NEOTIC®, PEDIADERM™ HC COMPLETE KIT for atopic dermatitis, FLUORADAY® for fluoride supplementation, and RHINARIS® and SALTAIRE® for nasal hygiene.

For more information regarding Arbor Pharmaceuticals or any of its products, visit www.arborpharma.com or send email inquiries to [email protected].

SOURCE Arbor Pharmaceuticals

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED